.png)
Direct Healthcare Professional Communication (DHPC) - Finasteride, dutasteride – New measures to minimise the risk of suicidal ideation - Direct Healthcare Professional Communication (DHPC) - Finasteride, dutasteride – New measures to minimise the risk of suicidal ideation
Direct Healthcare Professional Communication (DHPC) - Finasteride, dutasteride – New measures to minimise the risk of suicidal ideation
The use of finasteride, especially in 1 mg oral formulations for androgenetic alopecia, may be associated with suicidal ideation and depression, sometimes also related to sexual dysfunction. Patients should stop the treatment immediately and consult a doctor if they experience any of these symptoms.
A patient card will be included in the 1 mg finasteride package to help patients recognize these symptoms and know how to act.
For dutasteride, although the available evidence is not sufficient to establish a direct association with suicidal ideation, based on the common mechanism of action of medicines belonging to the class of 5-alpha reductase inhibitors, it is recommended to pay attention and contact a doctor if mood changes occur.
Published on: 16 September 2025